Desentum Oy
Announced 12 Oct 2026$31.5M · Manufacturing · Finland
Desentum is a research-oriented, clinical-stage biopharmaceutical company specialized in developing innovative allergen immunotherapy products that are based on switching the immune system’s response to allergens from hy
“We’re thrilled to announce that Desentum has closed an oversubscribed €28 million equity round, one of the largest ever raised by a privately held Finnish drug development company. This funding allows us to advance all three of our lead programmes, targeting birch, peanut and cat allergy.”
5 more sources tracked. Read the full press release and reporter coverage.
Sign up to read →Investors: Springvest Oyj.
Carbonfarm
